Sign in or create an account to add this stock to your watchlist.
About Penumbra (NYSE:PEN)
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:PEN
CUSIPN/A
Phone510-748-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio7.72
Quick Ratio5.84
Price-To-Earnings
Trailing P/E Ratio-15,760.00
Forward P/E Ratio927.06
P/E Growth47.95
Sales & Book Value
Annual Sales$333.76 million
Price / Sales16.18
Cash Flow$0.1224 per share
Price / Cash1,287.65
Book Value$11.80 per share
Price / Book13.36
Profitability
EPS (Most Recent Fiscal Year)($0.01)
Net Income$4.65 million
Net Margins3.65%
Return on Equity1.13%
Return on Assets0.96%
Miscellaneous
Employees1,700
Outstanding Shares34,260,000
Penumbra (NYSE:PEN) Frequently Asked Questions
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra (NYSE:PEN) posted its quarterly earnings results on Tuesday, May, 8th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.08. The business had revenue of $102.70 million for the quarter, compared to analyst estimates of $90.98 million. Penumbra had a return on equity of 1.13% and a net margin of 3.65%. The firm's revenue was up 40.3% on a year-over-year basis. During the same period last year, the company earned ($0.10) EPS. View Penumbra's Earnings History.
What price target have analysts set for PEN?
6 brokers have issued 12-month price objectives for Penumbra's shares. Their predictions range from $138.00 to $165.00. On average, they expect Penumbra's share price to reach $147.00 in the next year. View Analyst Ratings for Penumbra.
What are Wall Street analysts saying about Penumbra stock?
Here are some recent quotes from research analysts about Penumbra stock:
- 1. According to Zacks Investment Research, "Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. " (5/12/2018)
- 2. Canaccord Genuity analysts commented, "We would stay buyers of PEN, which continues to be a top pick in S/Mid-cap med-tech. We picked up notable legislative progress out of Tennessee both noteworthy and positive for PEN as well as the AIS market in general." (4/5/2018)
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED), Haemonetics (HAE), Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO) and iRhythm (IRTC).
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Mr. Adam Elsesser, Co Founder, Chairman, Chief Exec. Officer and Pres (Age 56)
- Dr. Arani Bose M.D., Co-Founder, Chief Innovator and Director (Age 56)
- Mr. Sridhar N. Kosaraju, Chief Financial Officer and Head of Strategy (Age 40)
- Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 57)
- Mr. Daniel Donen Davis, Chief Commercial Officer & Pres of North America (Age 40)
Has Penumbra been receiving favorable news coverage?
Headlines about PEN stock have trended somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Penumbra earned a news impact score of 0.22 on Accern's scale. They also gave media stories about the company an impact score of 45.67 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Penumbra's major shareholders?
Penumbra's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.31%), Baillie Gifford & Co. (1.70%), Lord Abbett & CO. LLC (1.62%), Redmile Group LLC (1.60%), Federated Investors Inc. PA (1.28%) and Eagle Asset Management Inc. (1.23%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.
Which institutional investors are selling Penumbra stock?
PEN stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Lord Abbett & CO. LLC, Redmile Group LLC, Rock Springs Capital Management LP, OppenheimerFunds Inc., Federated Investors Inc. PA, Russell Investments Group Ltd. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Insider Buying and Selling for Penumbra.
Which institutional investors are buying Penumbra stock?
PEN stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Summit Trail Advisors LLC, BlackRock Inc., Royal Bank of Canada, California Public Employees Retirement System, Point72 Asset Management L.P., Stevens Capital Management LP and Seven Eight Capital LP. View Insider Buying and Selling for Penumbra.
How do I buy shares of Penumbra?
Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
One share of PEN stock can currently be purchased for approximately $157.60.
How big of a company is Penumbra?
Penumbra has a market capitalization of $5.42 billion and generates $333.76 million in revenue each year. The company earns $4.65 million in net income (profit) each year or ($0.01) on an earnings per share basis. Penumbra employs 1,700 workers across the globe.
How can I contact Penumbra?
Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]
MarketBeat Community Rating for Penumbra (PEN)
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Penumbra (NYSE:PEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Penumbra in the last 12 months. Their average twelve-month price target is $147.00, suggesting that the stock has a possible downside of 6.73%. The high price target for PEN is $165.00 and the low price target for PEN is $138.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.33 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $147.00 | $130.75 | $111.50 | $115.00 |
| Price Target Upside: | 6.73% downside | 7.92% upside | 13.72% upside | 1.41% upside |
Penumbra (NYSE:PEN) Consensus Price Target History
Penumbra (NYSE:PEN) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Penumbra (NYSE:PEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Penumbra (NYSE PEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.70%
Institutional Ownership Percentage: 75.44%
Penumbra (NYSE PEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/9/2018 | Lynn Rothman | EVP | Sell | 6,000 | $150.38 | $902,280.00 | 132,719 |  |
| 5/7/2018 | Lynn Rothman | EVP | Sell | 6,000 | $135.05 | $810,300.00 | 139,419 | |
| 5/4/2018 | Lynn Rothman | EVP | Sell | 4,900 | $135.04 | $661,696.00 | 139,419 | |
| 5/1/2018 | Robert D Evans | EVP | Sell | 5,000 | $125.69 | $628,450.00 | 17,225 | |
| 3/15/2018 | Lynn Rothman | EVP | Sell | 6,000 | $125.02 | $750,120.00 | 144,319 | |
| 3/12/2018 | Robert D Evans | EVP | Sell | 10,000 | $121.03 | $1,210,300.00 | 12,225 | |
| 3/6/2018 | Lynn Rothman | EVP | Sell | 3,727 | $115.01 | $428,642.27 | 153,155 | |
| 2/28/2018 | Lynn Rothman | EVP | Sell | 2,273 | $115.00 | $261,395.00 | 154,046 | |
| 1/29/2018 | Don W Kassing | Director | Sell | 2,000 | $100.94 | $201,880.00 | 2,648 | |
| 1/16/2018 | Daniel Donen Davis | Insider | Sell | 30,000 | $88.80 | $2,664,000.00 | | |
| 1/16/2018 | Lynn Rothman | EVP | Sell | 6,000 | $90.99 | $545,940.00 | 159,519 | |
| 1/2/2018 | Robert D Evans | EVP | Sell | 40,000 | $89.89 | $3,595,600.00 | 11,704 | |
| 1/2/2018 | Thomas Wilder | Director | Sell | 345 | $91.15 | $31,446.75 | | |
| 11/28/2017 | Adam Elsesser | CEO | Sell | 10,000 | $103.95 | $1,039,500.00 | 1,121,356 | |
| 11/28/2017 | Arani Bose | Insider | Sell | 10,927 | $103.96 | $1,135,970.92 | 639,527 | |
| 11/28/2017 | Sridhar Kosaraju | CFO | Sell | 6,026 | $103.83 | $625,679.58 | | |
| 11/24/2017 | Adam Elsesser | CEO | Sell | 10,135 | $105.10 | $1,065,188.50 | 1,133,672 | |
| 11/24/2017 | James Robert Pray | Insider | Sell | 5,088 | $105.26 | $535,562.88 | 523,894 | |
| 11/24/2017 | Sridhar Kosaraju | CFO | Sell | 4,818 | $105.10 | $506,371.80 | | |
| 11/22/2017 | Adam Elsesser | CEO | Sell | 5,051 | $105.98 | $535,304.98 | 1,133,672 | |
| 11/22/2017 | Arani Bose | Insider | Sell | 6,248 | $106.10 | $662,912.80 | 652,118 | |
| 11/22/2017 | Sridhar Kosaraju | CFO | Sell | 2,600 | $105.99 | $275,574.00 | | |
| 11/21/2017 | Bridget O'rourke | Director | Sell | 429 | $106.60 | $45,731.40 | | |
| 11/20/2017 | Adam Elsesser | CEO | Sell | 62,862 | $105.15 | $6,609,939.30 | 1,191,887 | |
| 11/20/2017 | Arani Bose | Insider | Sell | 47,136 | $105.15 | $4,956,350.40 | 700,815 | |
| 11/20/2017 | Sridhar Kosaraju | CFO | Sell | 21,956 | $105.27 | $2,311,308.12 | | |
| 11/17/2017 | Adam Elsesser | CEO | Sell | 11,186 | $103.56 | $1,158,422.16 | 1,191,887 | |
| 11/17/2017 | Arani Bose | Insider | Sell | 8,133 | $103.50 | $841,765.50 | 700,815 | |
| 11/17/2017 | Sridhar Kosaraju | CFO | Sell | 4,290 | $103.52 | $444,100.80 | | |
| 11/15/2017 | Adam Elsesser | CEO | Sell | 24,444 | $105.83 | $2,586,908.52 | 1,231,338 | |
| 11/15/2017 | Arani Bose | Insider | Sell | 16,452 | $105.89 | $1,742,102.28 | 728,680 | |
| 11/15/2017 | Sridhar Kosaraju | CFO | Sell | 10,900 | $105.89 | $1,154,201.00 | | |
| 10/5/2017 | Harpreet Grewal | Director | Sell | 500 | $92.90 | $46,450.00 | | |
| 10/2/2017 | Thomas Wilder | Director | Sell | 345 | $90.20 | $31,119.00 | | |
| 9/29/2017 | Robert D Evans | EVP | Sell | 20,017 | $90.03 | $1,802,130.51 | 11,704 | |
| 9/28/2017 | Robert D Evans | EVP | Sell | 2,108 | $90.00 | $189,720.00 | 11,704 | |
| 9/27/2017 | Robert D Evans | EVP | Sell | 1,586 | $90.00 | $142,740.00 | 11,704 | |
| 9/21/2017 | Robert D Evans | EVP | Sell | 4,983 | $90.00 | $448,470.00 | 11,704 | |
| 9/20/2017 | Robert D Evans | EVP | Sell | 2,859 | $90.00 | $257,310.00 | 11,704 | |
| 8/21/2017 | Harpreet Grewal | Director | Sell | 4,500 | $82.65 | $371,925.00 | | |
| 8/9/2017 | Robert D Evans | EVP | Sell | 10,000 | $85.15 | $851,500.00 | 11,704 | |
| 8/1/2017 | Daniel Donen Davis | Insider | Sell | 32,000 | $79.42 | $2,541,440.00 | | |
| 7/18/2017 | Thomas Wilder | Director | Sell | 345 | $86.10 | $29,704.50 | | |
| 4/24/2017 | Robert D Evans | EVP | Sell | 10,000 | $85.24 | $852,400.00 | 12,075 | |
| 2/14/2017 | Robert D Evans | EVP | Sell | 5,000 | $75.00 | $375,000.00 | 7,075 | |
| 2/13/2017 | Adam Elsesser | CEO | Sell | 7,700 | $72.21 | $556,017.00 | 1,241,938 | |
| 2/13/2017 | James Robert Pray | Insider | Sell | 1,700 | $73.04 | $124,168.00 | 543,778 | |
| 2/13/2017 | Sridhar Kosaraju | CFO | Sell | 1,600 | $72.94 | $116,704.00 | | |
| 2/10/2017 | James Robert Pray | Insider | Sell | 23,900 | $71.08 | $1,698,812.00 | 566,978 | |
| 2/10/2017 | Sridhar Kosaraju | CFO | Sell | 15,500 | $71.49 | $1,108,095.00 | | |
| 2/9/2017 | Arani Bose | Insider | Sell | 22,300 | $70.44 | $1,570,812.00 | 736,191 | |
| 2/9/2017 | Lynn Rothman | EVP | Sell | 2,700 | $70.20 | $189,540.00 | | |
| 2/7/2017 | James Robert Pray | Insider | Sell | 4,099 | $69.09 | $283,199.91 | 575,178 | |
| 2/7/2017 | Robert D Evans | EVP | Sell | 1 | $70.00 | $70.00 | 7,075 | |
| 2/6/2017 | Arani Bose | Insider | Sell | 17,100 | $70.01 | $1,197,171.00 | 736,691 | |
| 2/6/2017 | Lynn Rothman | EVP | Sell | 2,886 | $70.41 | $203,203.26 | | |
| 2/6/2017 | Sridhar Kosaraju | CFO | Sell | 100 | $70.00 | $7,000.00 | | |
| 2/3/2017 | James Robert Pray | Insider | Sell | 15,600 | $70.39 | $1,098,084.00 | 590,159 | |
| 2/3/2017 | Robert D Evans | EVP | Sell | 5,000 | $70.35 | $351,750.00 | 7,075 | |
| 2/3/2017 | Sridhar Kosaraju | CFO | Sell | 7,800 | $70.56 | $550,368.00 | | |
| 2/1/2017 | Adam Elsesser | CEO | Sell | 21,400 | $70.98 | $1,518,972.00 | 1,244,038 | |
| 2/1/2017 | Daniel Donen Davis | Insider | Sell | 7,298 | $71.00 | $518,158.00 | | |
| 2/1/2017 | Lynn Rothman | EVP | Sell | 4,414 | $70.99 | $313,349.86 | | |
| 1/31/2017 | Adam Elsesser | CEO | Sell | 9,000 | $71.26 | $641,340.00 | 1,244,038 | |
| 1/31/2017 | Daniel Donen Davis | Insider | Sell | 3,000 | $71.29 | $213,870.00 | | |
| 1/31/2017 | Lynn Rothman | EVP | Sell | 1,800 | $71.27 | $128,286.00 | | |
| 1/30/2017 | Adam Elsesser | CEO | Sell | 8,200 | $70.72 | $579,904.00 | 1,244,038 | |
| 1/30/2017 | Daniel Donen Davis | Insider | Sell | 2,698 | $70.71 | $190,775.58 | | |
| 1/30/2017 | Lynn Rothman | EVP | Sell | 1,700 | $70.79 | $120,343.00 | | |
| 1/27/2017 | Arani Bose | Insider | Sell | 31,500 | $74.12 | $2,334,780.00 | 748,691 | |
| 1/27/2017 | Lynn Rothman | EVP | Sell | 7,000 | $74.24 | $519,680.00 | | |
| 1/26/2017 | Don W Kassing | Director | Sell | 3,000 | $74.50 | $223,500.00 | 2,666 | |
| 11/16/2016 | Sridhar Kosaraju | CFO | Sell | 25,000 | $65.07 | $1,626,750.00 | | |
| 9/9/2016 | Adam Elsesser | CEO | Sell | 57,200 | $71.07 | $4,065,204.00 | 1,249,838 | |
| 9/6/2016 | Arani Bose | Insider | Sell | 61,000 | $70.72 | $4,313,920.00 | 742,891 | |
| 9/2/2016 | Robert D Evans | EVP | Sell | 3,100 | $70.10 | $217,310.00 | 2,538 | |
| 8/31/2016 | Adam Elsesser | CEO | Sell | 26,000 | $71.15 | $1,849,900.00 | 1,244,838 | |
| 8/31/2016 | Robert D Evans | EVP | Sell | 5,300 | $71.17 | $377,201.00 | 2,538 | |
| 8/26/2016 | Adam Elsesser | CEO | Sell | 26,800 | $71.06 | $1,904,408.00 | 1,244,638 | |
| 8/26/2016 | Robert D Evans | EVP | Sell | 5,300 | $71.03 | $376,459.00 | 2,538 | |
| 8/24/2016 | Adam Elsesser | CEO | Sell | 29,000 | $72.95 | $2,115,550.00 | 1,245,938 | |
| 8/24/2016 | Robert D Evans | EVP | Sell | 6,300 | $73.00 | $459,900.00 | 2,538 | |
| 5/23/2016 | Robert D Evans | EVP | Sell | 5,000 | $50.52 | $252,600.00 | 2,538 | |
| 5/19/2016 | Don W Kassing | Director | Sell | 3,000 | $48.63 | $145,890.00 | 4,000 | |
| 5/19/2016 | Robert D Evans | EVP | Buy | 1,538 | $25.50 | $39,219.00 | 2,538 | |
| 5/16/2016 | James Robert Pray | Insider | Sell | 32,500 | $48.51 | $1,576,575.00 | 631,770 | |
(Data available from 1/1/2013 forward)
Penumbra (NYSE PEN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Penumbra (PEN) Expected to Post Quarterly Sales of $102.24 Million
www.americanbankingnews.com - May 17 at 4:17 AM |
 | Is Penumbra Inc’s (NYSE:PEN) Liquidity Good Enough?
finance.yahoo.com - May 16 at 9:26 AM |
| Penumbra (PEN) Expected to Announce Earnings of $0.03 Per Share
www.americanbankingnews.com - May 15 at 9:59 AM |
| Penumbra (PEN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 12 at 12:39 PM |
 | Penumbra's (PEN) CEO Adam Elsesser on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 9:49 AM |
| Penumbra (PEN) Upgraded by Zacks Investment Research to Strong-Buy
www.americanbankingnews.com - May 11 at 12:49 PM |
| Penumbra to Post Q3 2018 Earnings of $0.02 Per Share, William Blair Forecasts (PEN)
www.americanbankingnews.com - May 11 at 10:15 AM |
| Lynn Rothman Sells 6,000 Shares of Penumbra (PEN) Stock
www.americanbankingnews.com - May 10 at 7:37 PM |
 | BRIEF-Penumbra, Inc. Reports Qtrly Earnings Per Share $0.15
www.reuters.com - May 10 at 4:51 PM |
| Penumbra (PEN) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - May 10 at 1:28 PM |
| Edited Transcript of PEN earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:26 AM |
| Q3 2019 Earnings Estimate for Penumbra (PEN) Issued By William Blair
www.americanbankingnews.com - May 10 at 8:57 AM |
| Penumbra (PEN) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 11:08 PM |
| Penumbra (PEN) PT Raised to $140.00
www.americanbankingnews.com - May 9 at 6:09 PM |
| Penumbra (PEN) PT Raised to $165.00
www.americanbankingnews.com - May 9 at 4:43 PM |
 | Penumbra, Inc. (PEN) Tops Q1 EPS by 17c, Beats on Revenues; Boosts FY18 Revenue Outlook Above Consensus
www.streetinsider.com - May 9 at 9:17 AM |
| Penumbra: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:17 AM |
| Penumbra (PEN) EVP Lynn Rothman Sells 6,000 Shares
www.americanbankingnews.com - May 8 at 10:28 PM |
| Penumbra (PEN) EVP Sells $661,696.00 in Stock
www.americanbankingnews.com - May 8 at 10:28 PM |
| How Did Penumbra Inc’s (NYSE:PEN) 1.16% ROE Fare Against The Industry?
finance.yahoo.com - May 8 at 4:41 PM |
| Penumbra, Inc. Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 4:41 PM |
| Penumbra (PEN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 7 at 8:06 AM |
| What's in Store for Penumbra (PEN) This Earnings Season?
finance.yahoo.com - May 4 at 4:37 PM |
| What's in Store for Penumbra (PEN) This Earnings Season?
finance.yahoo.com - May 4 at 4:37 PM |
| Penumbra (PEN) EVP Robert D. Evans Sells 5,000 Shares
www.americanbankingnews.com - May 3 at 10:15 PM |
| Penumbra, Inc. to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 2 at 4:44 PM |
| Penumbra (PEN) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 10:28 AM |
| $92.57 Million in Sales Expected for Penumbra (PEN) This Quarter
www.americanbankingnews.com - April 29 at 2:14 AM |
| Penumbra (PEN) Expected to Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - April 27 at 9:10 PM |
| Penumbra, Inc. Schedules First Quarter 2018 Earnings Release and Conference Call for May 8, 2018
finance.yahoo.com - April 18 at 4:54 PM |
| Penumbra (PEN) versus Its Competitors Financial Analysis
www.americanbankingnews.com - April 16 at 7:07 PM |
| Penumbra (PEN) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 16 at 5:24 PM |
| Penumbra Inc (PEN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 8:49 AM |
| Penumbra Inc (PEN) Expected to Announce Quarterly Sales of $92.57 Million
www.americanbankingnews.com - April 12 at 1:48 AM |
| Brokerages Expect Penumbra Inc (PEN) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - April 10 at 11:21 PM |
| Penumbra's (PEN) Buy Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - April 5 at 1:57 PM |
| Penumbra (PEN) Research Coverage Started at Goldman Sachs
www.americanbankingnews.com - April 4 at 8:04 AM |
| Penumbra (PEN) PT Raised to $117.00
www.americanbankingnews.com - April 1 at 9:11 AM |
| Penumbra (PEN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:48 PM |
| $92.57 Million in Sales Expected for Penumbra Inc (PEN) This Quarter
www.americanbankingnews.com - March 26 at 1:50 AM |
| Analysts Anticipate Penumbra Inc (PEN) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - March 24 at 11:16 PM |
| Head-To-Head Contrast: Penumbra (PEN) vs. Its Peers
www.americanbankingnews.com - March 22 at 3:24 PM |
| With A -68.56% Earnings Drop, Did Penumbra Inc (NYSE:PEN) Really Underperform?
finance.yahoo.com - March 20 at 9:27 AM |
| Insider Selling: Penumbra Inc (PEN) EVP Sells 6,000 Shares of Stock
www.americanbankingnews.com - March 19 at 7:28 PM |
| Wells Fargo Boosts Penumbra (PEN) Price Target to $138.00
www.americanbankingnews.com - March 18 at 11:14 AM |
| Penumbra Inc (PEN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 18 at 8:54 AM |
| Robert D. Evans Sells 10,000 Shares of Penumbra Inc (PEN) Stock
www.americanbankingnews.com - March 14 at 7:12 PM |
| What Should We Expect From Penumbra Inc’s (NYSE:PEN) Earnings In The Year Ahead?
finance.yahoo.com - March 12 at 5:43 PM |
| Form 4 Penumbra Inc For: Mar 05 Filed by: Rothman Lynn
www.streetinsider.com - March 8 at 9:32 AM |
| Lynn Rothman Sells 3,727 Shares of Penumbra Inc (PEN) Stock
www.americanbankingnews.com - March 8 at 12:30 AM |
Penumbra (NYSE:PEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Penumbra (NYSE:PEN) Income Statement, Balance Sheet and Cash Flow Statement
Penumbra (NYSE PEN) Stock Chart for Monday, May, 21, 2018
Loading chart…
